Legal & General Group’s MBX Biosciences MBX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.19M Buy
21,583
+2,225
+11% +$77.7K ﹤0.01% 2132
2026
Q1
$578K Buy
19,358
+16,819
+662% +$572K ﹤0.01% 2320
2025
Q4
$80.1K Buy
2,539
+1,211
+91% +$29.4K ﹤0.01% 2657
2025
Q3
$23.2K Sell
1,328
-223
-14% -$2.98K ﹤0.01% 2981
2025
Q2
$17.7K Buy
1,551
+444
+40% +$4.52K ﹤0.01% 3061
2025
Q1
$8.17K Hold
1,107
﹤0.01% 3213
2024
Q4
$20.4K Sell
1,107
-3,893
-78% -$83K ﹤0.01% 3012
2024
Q3
$128K Buy
+5,000
New +$114K ﹤0.01% 2714

Other funds holding MBX

Legal & General Group's MBX Position: Q2 2026 in Review

Legal & General Group increased its MBX Biosciences (MBX) stake by 11% in Q2 2026, buying an estimated $77.7K and bringing the position to 21,583 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2132.

Legal & General Group first reported a position in MBX in Q3 2024 and has held it in 8 quarters since. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Legal & General Group held 21,583 shares of MBX Biosciences worth $1.19M as of Q2 2026.
  • Legal & General Group bought 2,225 MBX Biosciences shares in Q2 2026, an estimated $77.7K.
  • MBX Biosciences made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2132 holding.
  • Legal & General Group first reported a position in MBX Biosciences in Q3 2024 and has held it in 8 quarters since.
  • 172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.